Research programme: antifungals - Biosergen

Drug Profile

Research programme: antifungals - Biosergen

Alternative Names: BSG 005; BSG 005G

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Biosergen
  • Class Macrolides; Polyenes
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Mycoses

Highest Development Phases

  • No development reported Mycoses

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Mycoses in Norway
  • 03 Apr 2013 Research programme: antifungals - Biosergen is available for licensing as of 03 Apr 2013. www.biosergen.no
  • 02 Apr 2013 Preclinical trials in Mycoses in Norway (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top